Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Gynecologic Oncology Group · Indiana University – Purdue University Indianapolis
Abstract
PURPOSE: To determine whether cisplatin plus paclitaxel (C+P) improved response rate, progression-free survival (PFS), or survival compared with cisplatin alone in patients with stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix. PATIENTS AND METHODS Eligible: patients with measurable disease, performance status (PS) 0 to 2, and adequate hematologic, hepatic, and renal function received either cisplatin 50 mg/m2 or C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2) every 3 weeks for six cycles. Tumor measurements and quality-of-life (QOL) assessments were obtained before each treatment cycle. RESULTS: Of 280 patients entered, 6% were ineligible. Among 264 eligible patients, 134 received…
Citation impact
- FWCI
- 23.37
- Percentile
- 100%
- References
- 22
Authors
11- DHDavid H. MooreCorresponding
Gynecologic Oncology Group, Indiana University – Purdue University Indianapolis
- JAJohn A. Blessing
Gynecologic Oncology Group, Indiana University – Purdue University Indianapolis
- RPRichard P. McQuellon
Gynecologic Oncology Group, Indiana University – Purdue University Indianapolis
- HTHoward T. Thaler
Gynecologic Oncology Group, Indiana University – Purdue University Indianapolis
- DCDavid Cella
Gynecologic Oncology Group, Indiana University – Purdue University Indianapolis
Topics & keywords
- Medicine
- Cisplatin
- Neutropenia
- Internal medicine
- Gynecologic oncology
- Oncology
- Chemotherapy
- Gastroenterology
- Good health and well-being